Boston Scientific Enteryx GERD Device Clears FDA With Limited Indication
This article was originally published in The Gray Sheet
Executive Summary
Patients who respond to pharmacological treatments for gastroesophageal reflux disease (GERD) have a new therapeutic alternative in Boston Scientific's Enteryx injectable treatment system
You may also be interested in...
Patient-Reported Outcomes In Device Trials: FDA Guidance Under Review
FDA is reviewing a draft guidance on use of patient-reported outcome data in device evaluations, according to Division of Cardiovascular Devices Medical Officer Neal Muni, MD
Patient-Reported Outcomes In Device Trials: FDA Guidance Under Review
FDA is reviewing a draft guidance on use of patient-reported outcome data in device evaluations, according to Division of Cardiovascular Devices Medical Officer Neal Muni, MD
Boston Scientific Enteryx
Gastroesophageal reflux disease treatment gains newly assigned CPT code, permitting reimbursement under the hospital outpatient prospective payment system in 2004. The liquid polymer earned FDA approval in April (1"The Gray Sheet" April 28, 2003, p. 6)...